23 results on '"Biglietto M"'
Search Results
2. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX
3. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial
4. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
5. The therapy of kidney cancer with biomolecular drugs
6. Target therapy in metastatic renal cell carcinoma
7. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: A phase II study of the Southern Italy Cooperative Oncology Group (SICOG)
8. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase II–III randomized trial
9. P-66 Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population
10. A7 - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
11. 546P - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial
12. 548P - Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by next generation sequencing (NGS) in the CAPRI- GOIM trial
13. D02* - Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial
14. E04 - Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study
15. LBA-09 Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab
16. Biweekly irinotecan (IRI) with 6s-folinic acid (FA)-modulated 5-fluorouracil (FU) i.v. bolus in advanced colorectal carcinoma (ACC): a phase III study
17. Docetaxel (DTX) + cisplatin (CDDP) in locally advanced or metastatic head and neck cancer (HN). A phase II study
18. 747 - Biweekly administration of methotrexate (MTX), levofolinic acid (LFA), and 5-fluorouracil (5-FU) in advanced colorectal carcinomas
19. 714 - Phase II trial of paclitaxel (P) and cisplatin (COOP) in patients with advanced breast cancer refractory to anthracycline (A) therapy
20. Sandostatin, a long acting somatostatin analogue, in the treatment of advanced metastatic prostatic cancer
21. A phase II study of octreotide in metastatic advanced prostatic cancer (MAPC)
22. Protracted infusion (PI) of 5-FU+FA in advanced colorectal cancer
23. Urinary metabolites of PGI α in patients with osteosarcoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.